The use of immunotherapy for patients with RAS/BRAF wild-type MSS CRC is being investigated beyond frontline therapy in a phase II clinical trial evaluating the combination of nivolumab and ipilimumab with panitumumab in patients who have received one or two prior lines of systemic treatment (NCT03442569). This evidence concerns the gene BRAF and colorectal carcinoma.